Please assess the completion status of the following clinical trial:

Trial Title: Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.~2. Male and Female subjects between 18 and 45 years~3. WRAT-4 Reading \[127\] standard score \> 85~4. Able to undergo neuroimaging data collection procedures. For MS Participants~5. Definite diagnosis of RRMS \[128\]~6. EDSS of 0 to 6.0~7. Adequate vision as as reported by the participant (with correction if applicable)~8. Clinically prescribed Tecfidera, Tysabri or Ocrevus therapy by treating neurologist, with first dose being within 3 months + 14 days from baseline visit~9. At baseline visit, concurrent medications to be kept constant over three months prior to data collection visits~10. No relapse or steroids in previous month~Exclusion Criteria:~1. Unable or unwilling to provide informed consent.~2. Beck Depression Inventory-Fast Screen (BDI-FS) \[129, 130\] score of 4 or more~3. Current alcohol or other substance use disorder~4. Primary psychiatric disorder that would adversely influence ability to participate~5. Other neurological condition associated with cognitive impairment (e.g., epilepsy, brain injury)~6. Other serious uncontrolled medical condition (e.g., cancer or acute myocardial infarction)~7. Learned English language after 12 years of age~8. For low absolute low lymphocyte count (ALC), USPI guidance will be utilized.~   For MS participants:~9. Lemtrada, Cladribine, Mitoxantrone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- MS Patients (Type: None): Definite diagnosis of RRMS
- Healthy Controls (Type: None): gender aged match healthy

Based on this trial design, predict the completion outcome and termination type (if applicable).